High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03449056

Acronym

OPTINEB

Enrollment

Registered

2018-02-28

Start date

2019-01-11

Completion date

2020-04-30

Last updated

2019-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, High-flow Nasal Cannula

Brief summary

High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns de novo acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied. Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.

Interventions

DRUGsalbutamol

T2 - T1+1h30: High-nasal flow and salbutamol nebulization

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Arterial pH over 7.25, * Respiratory rate under 35 breaths/mn * Glasgow Coma Scale equal to 15, * indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours), * NIV sessions spaced more than 6 hours.

Exclusion criteria

* Urgent endotracheal intubation; * Contraindication to beta 2 adrenergic agonist; * Another organ failure (hemodynamic and neurological instability); * Cardioselective beta-blocker during treatment of copd exacerbation;

Design outcomes

Primary

Measure	Time frame	Description
compare lung functions	baseline-1h30	Evolution of Forced Expiratory Volume 1s

Countries

France

Contacts

Primary ContactJean-Pierre FRAT

jean-pierre.frat@chu-poitiers.fr+33549442830

Backup Contactnicolas MARJANOVIC

nicolas.marjanovic@chu-poitiers.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026